This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

开始日期2026-01-01

申办/合作机构

Stony Brook University

NCT05367362

/ Not yet recruiting临床2期IIT

Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included. The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days. The control group will receive standard medical and endovascular care along with a similar looking placebo. Patients will be randomized to the treatment or control group by the Pharmacy eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients further minimizing the bias. Through randomization we expect to achieve two groups that are comparable in their baseline clinical characteristics.

开始日期2025-12-01

申办/合作机构

State University of New York at Buffalo

NCT07082855

/ Not yet recruiting临床3期IIT

A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety?100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.

开始日期2025-07-15

申办/合作机构

中山大学中山眼科中心

100 项与盐酸米诺环素相关的临床结果

登录后查看更多信息

100 项与盐酸米诺环素相关的转化医学

登录后查看更多信息

100 项与盐酸米诺环素相关的专利（医药）

登录后查看更多信息

11,281

项与盐酸米诺环素相关的文献（医药）

2025-12-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Protective effects of minocycline on dermal fibroblast cells from oxidant and apoptotic effects of H2O2: A comprehensive analysis with Raman spectroscopy and data-driven approach

Article

作者: Celik, Nusret ; Onses, Mustafa Serdar ; Sahin, Furkan ; Sezer, Gulay

Minocycline (Mino) is an antibiotic with neuroprotective, anti-inflammatory, and antioxidant properties. This study investigated the protective effects of Mino against hydrogen peroxide (H₂O₂)-induced oxidative damage in dermal fibroblast cells and analyzed these effects using Raman spectroscopy, principal component analysis (PCA), and machine learning (ML). L929 fibroblast cells were evaluated using MTT and scratch wound-healing assays. The production of reactive oxygen species (ROS) and the process of apoptosis were evaluated through the use of 2',7'-dichlorofluorescein diacetate (DCFH-DA) and Annexin V labelling, respectively. The mRNA expression levels of Nrf2, Hmox1, Nqo1, and Col1a were analyzed through quantitative real-time polymerase chain reaction (qRT-PCR). Raman spectroscopy detected molecular alterations, while PCA and ML classified spectral variations. Mino reduced H₂O₂-induced cellular toxicity, ROS levels, and apoptosis while enhancing fibroblast migration. It significantly upregulated Nrf2 and Hmox1 mRNA under oxidative stress and increased Col1a expression when applied alone. Raman spectroscopy revealed biochemical changes in lipids, proteins, and nucleic acids. PCA distinguished treatment groups, showing Mino-treated cells closely resembled controls. The SVM attained 90.10 % classification accuracy, underscoring the efficacy of Raman-based computational analysis. The findings collectively highlight the potential of Raman spectroscopy, PCA, and ML as a sensitive, label-free approach for monitoring molecular changes, thereby supporting the therapeutic potential of Mino in oxidative stress-related therapies.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates

Article

作者: Ahmed, Iftikhar ; Ahmad, Aftab ; Saeed, Muhammad ; Shafiq, Muhammad ; Latif, Kunza ; Hyder, Muhammad Zeeshan

OBJECTIVES:

Drug-resistant Enterobacterales carrying carbapenem-resistant genes cause severe infections in clinical settings worldwide. Among these, the New Dehli Metallo-β-lactamase (bla_NDM) gene is significantly prevalent and associated with high morbidity. This study was designed to investigate the susceptibility profiling of Carbapenem-Resistant-Enterobacterales (CRE), prevalence of bla_NDM and its variants, and associated risk factors.

METHODS:

CRE isolates from a tertiary care hospital, in Islamabad, Pakistan, were identified and the susceptibility testing was performed using disc diffusion method. MICs were determined for imipenem, tigecycline, and colistin through E-strips and microbroth dilution method respectively. For molecular characterization and typing of the bla_NDM gene, PCR products were sequenced, and the phylogenetic analysis was performed using MEGA ver 6.0 software.

RESULTS:

Among 5,134 clinical samples, 42.13% (n = 2,163) yielded pathogens including 42.58% (n = 921) Enterobacterales. On further screening, 39.52% (n = 364) of Enterobacterales were identified as CRE. The bla_NDM gene was detected in 75.27% (n = 274) in CRE isolates, comprising bla_NDM-1 (44%), bla_NDM-5 (53%), and bla_NDM-7 (3%) variants. Tigecycline (86.7%) and colistin (100%) were most effective antimicrobial agents with MICs ranging from 0.064 to 8 and 0.125-1 µg/ml respectively. bla_NDM-1-harboring bacteria exhibited high antimicrobial resistance compared to bla_NDM-5 and bla_NDM-7. Cefiderocol was 75.6% and ceftazidime/avibactam with aztreonam was 97.08% effective against bla_NDM-harboring bacteria. The phylogenetic analysis indicated that bla_NDM variants showed close genetic relationships and homology to the previously described sequences in GenBank databases having diverse connection with worldwide sequences.

CONCLUSION:

The high prevalence of bla_NDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving bla_NDM gene, which is essential for effective clinical management.

2025-10-01·Journal of Computational Biophysics and Chemistry

Utilizing Non-β-Lactam Antibiotics to Combat Antimicrobial Resistance by Targeting Multiple Virulence Factors of Pseudomonas aeruginosa

作者: Arshad, Mohammed ; Husain, Fohad Mabood ; Parveen, Nagma ; Furkan, Mohammad ; Khan, Altaf ; Khan, Rizwan Hasan ; Qais, Faizan Abul ; Ahmad, Iqbal ; Adil, Mohd

In pre-antibiotic times, various highly contagious diseases like cholera, smallpox and tuberculosis were widespread worldwide. Penicillin discovery in the late 1920s was a groundbreaking moment in medical history, saving countless lives. However, over the next few decades, microbes developed antibiotic resistance, leading to a global public health threat known as antimicrobial resistance (AMR). Pseudomonas aeruginosa is a major contributor to hospital-acquired infections, affecting millions of patients and causing numerous deaths annually. Several non-[Formula: see text]-lactam antibiotics combat these infections effectively, while their effect on P. aeruginosa quorum sensing (QS) has been insufficiently explored. We have undertaken comprehensive research to understand the effect of non-[Formula: see text]-lactam antibiotics on various targets of P. aeruginosa. Using molecular simulations, we scrutinize these antibiotics” dynamic behavior and stability. Based on toxicity, binding energy and binding site, platensimycin and sulfasalazine were identified as promising candidates against various targets of P. aeruginosa. The binding energies for sulfasalazine and platensimycin with LasA were found to be −8.1 and −8.6 kcal/mol, respectively. Both of these leading antibiotics were interacting at the active sites of all tested proteins (LasA, LasI and PqsR). The examination of molecular dynamics confirmed the stable complex formation of the lead non-[Formula: see text]-lactam antibiotics with all selected target proteins under normal physiological conditions. These findings emphasize the potential efficacy of platensimycin and sulfasalazine. They could potentially be repurposed for targeting the QS of P. aeruginosa.

155

项与盐酸米诺环素相关的新闻（医药）

2025-07-22

·GBIHealth

阿斯利康拟至2030年在美国投资500亿美元用于药品制造与研发

药械追踪No.1 / 罗氏基因泰克披露艾特利单抗治疗COPD最新试验结果2025年7月21日，罗氏（SIX: RO, ROG; OTCQX: RHHBY）旗下基因泰克（Genentech）公布艾特利单抗（astegolimab）治疗中至重度慢性阻塞性肺疾病（COPD）的两项关键临床试验结果：IIb期ALIENTO研究达到主要终点，III期ARNASA研究则未达到主要终点。ALIENTO研究共纳入1301例COPD患者，结果显示，艾特利单抗每两周给药一次，可在52周内使年化加重发作率（AER）显著下降15.4%。相比之下，ARNASA研究共纳入1375例患者，尽管观察到14.5%的AER下降，但未达到统计学显著性，未能满足主要终点。两项研究人群均为既往或当前吸烟者，不考虑血液嗜酸性粒细胞计数，均有频繁发作史，并接受标准维持治疗（包括ICS、LABA、LAMA的不同组合）。两项试验中发作事件总数均低于预期，艾特利单抗的安全性与既往研究一致，未发现新的安全风险。艾特利单抗是一种在研的全人源抗 ST2 单克隆抗体，旨在与 ST2 受体高亲和力结合，从而阻断 IL-33 信号传导。基因泰克表示，后续将与监管机构就这些数据展开讨论，并在即将召开的医学会议上披露详细结果。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / 赛诺菲16亿美元收购Vicebio，囊获分子夹技术开发下一代多价疫苗2025年7月22日，Vicebio Ltd与赛诺菲签署了一项独家、最终收购协议。根据协议条款，在满足惯例条件的情况下，Vicebio的股东将获得总计最高达16亿美元的款项，其中包括11.5亿美元的预付款，以及4.5亿美元的开发和监管里程碑款项。Vicebio是一家创新生物制药公司，旨在利用其专有的分子夹（Molecular Clamp）技术，开发针对危及生命的呼吸道病毒感染的下一代疫苗。分子夹技术由昆士兰大学研发，能够独特地稳定病毒糖蛋白，激发强烈的保护性免疫反应，并实现高产量生产，可用于制备即用型液体多价疫苗。目前，Vicebio正在对其先导产品VXB-241开展探索性I期临床试验，这是一款针对RSV和hMPV病毒的二价疫苗。I期临床试验中期分析显示，VXB-241在60岁及以上成年人中具有良好的安全性和耐受性。->点击文末阅读原文，解锁完整双语新闻No.2 / 上药控股与科笛生物达成创新药进口分销战略合作2025年7月21日，上药控股（2607.HK，601607.SH）与科笛生物（2487.HK）签约，双方将围绕科笛生物创新药品“非那雄胺喷雾剂”“盐酸米诺环素泡沫剂”在中国大陆的进口及总经销展开深入合作。上药控股将为科笛生物提供保税进口、全国分销、供应链优化以及创新增值服务，加速科笛生物产品的商业化进程。->点击文末阅读原文，解锁完整双语新闻No.3 / 阿斯利康拟至2030年在美国投资500亿美元用于药品制造与研发2025年7月21日，阿斯利康（AstraZeneca，LSE/STO/Nasdaq：AZN）宣布计划到2030年在美国投资500亿美元，用于扩大药品生产与研发布局，支持其2030年实现800亿美元总营收的目标，其中预计50%将来自美国市场。本次投资的核心为在弗吉尼亚州建设一座全新的数十亿美元级药物原料生产中心，这是公司迄今在全球最大规模的单项生产投资。该工厂将用于生产阿斯利康创新的代谢和体重管理药物组合中的原料，包括口服GLP-1、baxdrostat、口服PCSK9及小分子联合制剂等，涉及小分子、肽类与寡核苷酸等多种药物形态。该设施还将充分运用人工智能、自动化与数据分析技术提升生产效率。除弗吉尼亚新建原料药工厂外，阿斯利康还将在马里兰、马萨诸塞、加州、印第安纳和德州等地扩建研发和生产设施，进一步完善其在美的研发制造布局。阿斯利康目前在美设有19处研发、生产与商业运营基地，员工超1.8万人，支持超过9.2万个直接与间接岗位。2024年公司对美国经济的直接贡献达50亿美元，总体带动价值约200亿美元。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ olivia.xu@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

并购疫苗临床2期临床3期临床1期

2025-07-14

·GlobeNewswire-Health Care

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company’s recently launched treatment for the inflammatory lesions of rosacea in adults. This compares to 29% of commercial lives in May 2025. Journey Medical continues to execute on the launch of Emrosi, with expanded payer coverage anticipated to facilitate further growth in total prescription (TRx) demand. “We are extremely pleased with the ongoing adoption of Emrosi by commercial payers, which is being driven by our targeted contracting strategy, increasing prescription demand, and strong clinical data demonstrating superior efficacy of Emrosi over the current standard of care,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Delivering cost-effective coverage for high-quality dermatologic medicines is a core priority for Journey Medical, and our strong progress with payers and our patient access program both help to ensure that patients receiving a prescription for Emrosi are able to benefit from this best-in-class medicine. We look forward to continuing to expand coverage for Emrosi for patients nationwide, and believe that the product will become the standard of care for the treatment of rosacea.” Emrosi is available by prescription at specialty pharmacy chains. About RosaceaRosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects over 16 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition. Important Safety InformationIndication: EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. For full prescribing information, please visit www.emrosi.com. About Journey Medical CorporationJourney Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com. Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, EmrosiTM, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact:Jaclyn Jaffe (781) 652-4500ir@jmcderm.com Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

2025-07-13

·信狐药迅

两个1类新药：苏州亚盛力胜克拉片和苏州旺山旺水斯美瑞非片获批上市| 新获批(7.7-7.13）

每周药品注册获批数据，分门别类呈现，一目了然。(7.7-7.13）新药上市申请药品名称企业注册分类受理号力胜克拉片苏州亚盛药业有限公司1CXHS2400114力胜克拉片苏州亚盛药业有限公司1CXHS2400113力胜克拉片苏州亚盛药业有限公司1CXHS2400112斯美瑞非片苏州旺山旺水生物医药股份有限公司1CXHS2300087斯美瑞非片苏州旺山旺水生物医药股份有限公司1CXHS2300086斯美瑞非片苏州旺山旺水生物医药股份有限公司1CXHS2300085新药临床申请药品名称企业注册分类受理号DZD8586片迪哲(江苏)医药股份有限公司1CXHL2500453注射用JJH201601脂质体江苏吉贝尔药业股份有限公司1CXHL2500448CMS-D001片海南德镁医药科技有限责任公司1CXHL2500442CMS-D001片海南德镁医药科技有限责任公司1CXHL2500441注射用HRS8179北京盛迪医药有限公司1CXHL2500436MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500435MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500434MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500433MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500432SYN608片杭州圣域生物医药科技有限公司1CXHL2500430SYN608片杭州圣域生物医药科技有限公司1CXHL2500429G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2500425G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2500424PTT-621片北京炎明生物科技有限公司1CXHL2500399PTT-621片北京炎明生物科技有限公司1CXHL2500398GD-19乳状注射液天津谷堆生物医药科技有限公司2.1CXHL2500385OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500423OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500422OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500421ACIERT缓释片吉林天衡药业有限公司2.2CXHL2500412ACIERT缓释片吉林天衡药业有限公司2.2CXHL2500411甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司2.4CXHL2500419重组带状疱疹疫苗(CHO细胞)安徽智飞龙科马生物制药有限公司1.3CXSL2500282IBI130信达生物制药(苏州)有限公司1CXSL2500366注射用BG-C477广州百济神州生物制药有限公司1CXSL2500358重组抗CD19m-CD3抗体注射液天劢源和生物医药(上海)有限公司1CXSL2500355LP-005 注射液天辰生物医药(苏州)有限公司1CXSL2500354FG-B901注射液明济生物制药(北京)有限公司1CXSL2500352FL115注射液苏州复融生物技术有限公司1CXSL2500350注射用BGB-B3227广州百济神州生物制药有限公司1CXSL2500347注射用YL242苏州宜联生物医药有限公司1CXSL2500343IMD101 注射液上海英脉德医疗科技有限公司1CXSL2500339BBT001注射液杉竹曜(北京)生物医药科技有限公司1CXSL2500342注射用DB-1311映恩生物制药(苏州)有限公司1CXSL2500337YOLT-101注射液尧唐(南京)生物科技有限公司1CXSL2500313AL-001眼用注射液北京安龙合生药业有限公司1CXSL2500301DMR2301注射液上海多米瑞生物技术有限公司1CXSL2500308人脐带间充质干细胞注射液源品细胞生物科技集团有限公司1CXSL2500297注射用RGL-232上海瑞宏迪医药有限公司1CXSL2500295CRG-B191注射液上海科锐克医药科技有限公司1CXSL2500293QX029N注射液江苏荃信生物医药股份有限公司1CXSL2500288MSLN-CAR-T细胞注射液上海怡豪生物科技有限公司1CXSL2500281依沃西单抗注射液康方赛诺医药有限公司2.2CXSL2500345SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500340SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500338贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2500336阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500335仿制药申请药品名称企业注册分类受理号盐酸肾上腺素注射液成都瑞尔医药科技有限公司3CYHS2400548磷酸奥司他韦干混悬剂福建省闽东力捷迅药业股份有限公司3CYHS2400421二羟丙茶碱注射液安徽美来药业股份有限公司3CYHS2400281吡拉西坦注射液湖南赛隆药业(长沙)有限公司3CYHS2400261吡拉西坦注射液湖南赛隆药业(长沙)有限公司3CYHS2400260富马酸酮替芬口服溶液浙江易泽达医药科技有限公司3CYHS2303277氯化钾颗粒山西皇城相府药业股份有限公司3CYHS2303100氯化钾颗粒山西皇城相府药业股份有限公司3CYHS2303099头孢丙烯干混悬剂海南葫芦娃药业集团股份有限公司3CYHS2302198福多司坦片天方药业有限公司3CYHS2302051卡络磺钠注射液南京恩泰医药科技有限公司3CYHS2301863卡络磺钠注射液南京恩泰医药科技有限公司3CYHS2301862注射用水溶性维生素辽宁海思科制药有限公司3CYHS2301315氨溴特罗口服溶液北京韩美生物科技有限公司3CYHS2301124艾拉莫德片四川国为制药有限公司4CYHS2401588瑞舒伐他汀依折麦布片(I)浙江诺得药业有限公司4CYHS2401540注射用盐酸地尔硫䓬山东豪瑞恩制药有限公司4CYHS2401285氯化钾氯化钠注射液石家庄四药有限公司4CYHS2401230氯化钾氯化钠注射液石家庄四药有限公司4CYHS2401229贝前列素钠片江苏和晨药业有限公司4CYHS2401140盐酸决奈达隆片齐鲁制药有限公司4CYHS2401042普拉替尼胶囊基石药业(苏州)有限公司4CYHS2401036地夸磷索钠滴眼液苏州朗科生物技术股份有限公司4CYHS2400985左氧氟沙星氯化钠注射液辽宁民康制药有限公司4CYHS2400843尼可地尔片北京四环科宝制药股份有限公司4CYHS2400774阿哌沙班片浙江永宁药业股份有限公司4CYHS2400729磷酸奥司他韦胶囊吉林开曼药业有限公司4CYHS2400737注射用头孢唑肟钠广州合和医药有限公司4CYHS2400569盐酸尼卡地平注射液南京锐志生物医药有限公司4CYHS2400566氨氯地平阿托伐他汀钙片湖南威特制药股份有限公司4CYHS2400461聚乙二醇钠钾散四川科伦药业股份有限公司4CYHS2400408盐酸尼卡地平注射液浙江华海药业股份有限公司4CYHS2400383培哚普利氨氯地平片(I)天津力生制药股份有限公司4CYHS2400310培哚普利氨氯地平片(III)天津力生制药股份有限公司4CYHS2400309琥珀酸美托洛尔缓释片浙江华海药业股份有限公司4CYHS2303470二甲双胍恩格列净片(I)湖南及正医药科技有限公司4CYHS2303454注射用磷酸特地唑胺江苏正大丰海制药有限公司4CYHS2303356盐酸莫西沙星滴眼液扬州中宝药业股份有限公司4CYHS2303323孟鲁司特钠颗粒浙江易泽达医药科技有限公司4CYHS2303311贝美素噻吗洛尔滴眼液杭州民生药业股份有限公司4CYHS2303101盐酸乌拉地尔天方药业有限公司CYHS2360899四价流感病毒裂解疫苗浙江天元生物药业有限公司3.3CXSS2300101盐酸米诺环素泡沫剂上海则正医药科技股份有限公司4CYHL2500089盐酸米诺环素泡沫剂深圳珐玛易药品科技有限公司4CYHL2500087琥珀酰明胶电解质醋酸钠注射液四川太平洋药业有限责任公司4CYHL2500081噻托溴铵吸入粉雾剂艾特美(苏州)医药科技有限公司4CYHL2500077吸附破伤风疫苗远大赛威信生命科学(南京)有限公司3.3CXSL2500296进口申请药品名称企业注册分类受理号褪黑素颗粒Nobelpharma Co., Ltd.5.1JXHS2400013褪黑素颗粒Nobelpharma Co., Ltd.5.1JXHS2400012BPC2001注射液BioPhoenix Co., Ltd.1JXHL2500100BMS-986435片Bristol-Myers Squibb Company1JXHL2500086BMS-986435片Bristol-Myers Squibb Company1JXHL2500085BMS-986435片Bristol-Myers Squibb Company1JXHL2500084Capivasertib片AstraZeneca AB2.4JXHL2500109Capivasertib片AstraZeneca AB2.4JXHL250010821价肺炎球菌多糖结合疫苗Sanofi Pasteur Inc.1.4JXSL2500058Mezagitamab注射剂Takeda Development Center Americas, Inc.1JXSL2500066SAR442970注射液Sanofi-Aventis Recherche & Développement1JXSL2500062SAR442970注射液Sanofi-Aventis Recherche & Développement1JXSL2500059中药相关申请药品名称企业注册分类受理号香芩解热颗粒云南方盛融和药业有限公司1.1CXZL2500024健脾解毒丸新疆维吾尔自治区中医医院1.1CXZL2500021注：橙色字体部分结论为不批准或收到通知件；

上市批准疫苗

100 项与盐酸米诺环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00850	盐酸米诺环素	J01AA08 A01AB23	DB01017

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Journey Medical Corp.	2020-05-28
寻常痤疮	美国	Bausch Health US LLC	2006-05-08
炭疽	日本	Pfizer Japan, Inc.	2002-03-06
感染	中国	海口市制药厂有限公司	1992-01-01
地方性斑疹伤寒	日本	Pfizer Japan, Inc.	1989-09-01
鹦鹉热	日本	Pfizer Japan, Inc.	1985-11-05
急性支气管炎	日本	Pfizer Japan, Inc.	1979-04-20
细菌性阴道炎	日本	Pfizer Japan, Inc.	1979-04-20
膀胱炎	日本	Pfizer Japan, Inc.	1979-04-20
泪囊炎	日本	Pfizer Japan, Inc.	1979-04-20
附睾炎	日本	Pfizer Japan, Inc.	1979-04-20
淋病	日本	Pfizer Japan, Inc.	1979-04-20
睑腺炎	日本	Pfizer Japan, Inc.	1979-04-20
感染性肠炎	日本	Pfizer Japan, Inc.	1979-04-20
子宫内感染	日本	Pfizer Japan, Inc.	1979-04-20
颌骨炎症	日本	Pfizer Japan, Inc.	1979-04-20
喉炎	日本	Pfizer Japan, Inc.	1979-04-20
肺脓肿	日本	Pfizer Japan, Inc.	1979-04-20
淋巴结炎	日本	Pfizer Japan, Inc.	1979-04-20
乳腺炎	日本	Pfizer Japan, Inc.	1979-04-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
种植体周围炎	临床3期	美国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	德国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	瑞典	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	英国	OraPharma, Inc.	2012-04-01
慢性牙周炎	临床3期	美国	Sunstar Americas, Inc.	2006-01-01
侵袭性牙周炎	临床3期	美国	OraPharma, Inc.	2004-01-01
脓疱疮	临床2期	以色列	VYNE Therapeutics, Inc.	2010-08-01
肌萎缩侧索硬化	临床2期	美国	Pfizer Inc.	2006-07-01
急性肾损伤	临床1期	德国	Rempex Pharmaceuticals, Inc.	2017-05-29
过敏性皮肤反应	临床1期	-	VYNE Therapeutics, Inc.	2016-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Phase II Trial Evaluating Minocycline for Geographic Atrophy (Pubmed \| Ophthalmol Sci)	临床2期	地图样萎缩	30	Minocycline 100 mg	鏇鑰鹹網壓遞廠築憲製(願繭顧餘構憲遞鬱繭鑰) = 鹹顧選範簾網鹹獵憲選顧夢願淵觸艱鹹糧願繭 (餘齋膚壓鏇構夢願構獵, 0.85) 更多	不佳	2025-09-01
NCT02213575 (CTgov)	临床2期	高血压	5	Minocycline (Minocycline Treatment Group)	繭獵築鑰鹽膚艱蓋選鏇(窪積鹽鑰壓鹹鹹膚壓襯) = 積鹹醖醖鏇蓋遞鬱壓鬱憲觸蓋顧糧膚艱夢齋蓋 (積製鹽積範鹹鑰夢糧鑰, 0.0292) 更多	-	2025-07-01
				minocycline (Control)	獵淵製願築鹹簾夢糧糧(積醖簾夢窪鹽網鏇餘願) = 醖艱顧鑰鏇蓋糧製製糧製積淵選淵齋窪鬱糧衊 (淵願積衊觸願鬱遞築憲, 糧積餘糧獵醖艱網夢糧 ~ 願糧廠選壓膚遞鑰製範) 更多
NCT03106740 (IGNITE, CTgov)	临床2期	腰痛 \| 急性腰痛 \| 慢性疼痛 ... 更多	60	Magnetic Resonance-Positron Emission Tomography Imaging+Minocycline Hydrochloride 100mg Capsule (Minocycline Arm)	夢願獵鑰繭鹽醖鑰鹽網(選獵齋餘顧網範構壓鹹) = 鑰顧簾鏇襯糧築獵膚衊醖範夢襯網壓壓獵衊窪 (憲築襯艱獵網築選淵壓, 0.051) 更多	-	2025-05-11
				Magnetic Resonance-Positron Emission Tomography Imaging (Placebo Arm)	夢願獵鑰繭鹽醖鑰鹽網(選獵齋餘顧網範構壓鹹) = 餘觸齋廠膚鬱糧獵艱糧醖範夢襯網壓壓獵衊窪 (憲築襯艱獵網築選淵壓, 0.056) 更多
NCT02203552 (CTgov)	临床2期	复发性乳腺癌 \| 抑郁症 \| 焦虑症 ... 更多	56	laboratory biomarker analysis+minocycline hydrochloride (Arm I (Minocycline Hydrochloride))	構醖衊餘顧憲鹽築鏇蓋(鑰網簾鏇衊鑰齋築築壓) = 艱鬱齋觸壓餘淵觸壓遞獵夢餘餘醖觸膚糧網築 (餘膚築齋衊簾壓簾獵網, 積齋襯築繭膚範艱鹹獵 ~ 積醖鹽願築選襯壓廠繭) 更多	-	2025-01-08
				placebo (Arm II (Placebo))	構醖衊餘顧憲鹽築鏇蓋(鑰網簾鏇衊鑰齋築築壓) = 糧積範簾願觸鹹顧簾鏇獵夢餘餘醖觸膚糧網築 (餘膚築齋衊簾壓簾獵網, 糧鹹顧繭繭構襯齋鹹鹹 ~ 範鏇積膚選憲簾積構簾) 更多
CTR20211291 (NEWS) 人工标引	临床3期	寻常痤疮	-	外用4%米诺环素泡沫剂	夢鬱製顧遞淵製鹽鹽壓(醖膚憲艱蓋餘選醖鹹衊): P-Value = <0.001 达到更多	积极	2024-07-30
				Placebo
NCT03762915 (CTgov)	临床4期	炎症	70	minocycline HCl microspheres (SRP With Minocycline HCl Microspheres)	鏇醖襯構觸鹽繭壓製網(壓網鹽醖糧憲製憲願獵) = 願鹹遞糧醖積鏇獵鑰獵鑰製夢糧繭鹽繭餘願餘 (築衊遞範鑰網鬱築壓鹽, 觸鏇鬱繭廠衊構糧積鑰 ~ 獵觸鹽壓觸醖鹹遞選餘) 更多	-	2024-03-25
				minocycline HCl (SRP Without Minocycline HCl Microspheres)	鏇醖襯構觸鹽繭壓製網(壓網鹽醖糧憲製憲願獵) = 憲窪壓齋艱獵鏇衊鏇艱鑰製夢糧繭鹽繭餘願餘 (築衊遞範鑰網鬱築壓鹽, 繭艱衊餘繭願窪鹹築鬱 ~ 遞觸鹽鬱襯範壓鏇鬱餘) 更多
Pubmed	临床2期	年龄相关性黄斑变性	37	Oral Minocycline 100 mg	範醖鹽選鹹獵網製鏇艱(齋夢餘願蓋憲製觸鬱鏇) = 積製鑰窪網艱遞顧糧淵網積願鹽齋齋艱齋糧夢 (顧壓鏇廠糧淵鑰壓齋窪 )	不佳	2024-03-14
NCT02564978 (CTgov)	临床2期	干性年龄相关性黄斑病变 \| 年龄相关性黄斑变性 \| 地图样萎缩	37	Minocycline	艱鏇襯壓糧網淵範遞遞(鏇願糧糧醖築蓋蓋獵鹹) = 窪簾鹽鏇夢繭糧廠構窪膚醖製餘艱鏇齋顧觸衊 (淵鹹網繭鑰製鹽願選網, 0.03) 更多	-	2024-02-01
NCT03320018 (H2M, CTgov)	临床2/3期	急性缺血性卒中	15	Hydrogen+Minocycline (Hydrogen/Minocycline)	積觸鬱築鬱淵壓鬱淵鬱 = 鹹遞窪齋膚膚構築網顧簾遞艱範衊鏇糧遞淵襯 (鬱壓夢齋鏇齋膚顧積顧, 齋獵糧顧膚鑰窪淵築廠 ~ 選壓製製鏇憲選醖襯艱) 更多	-	2023-12-19
				Placebo Hydrogen (Placebo Hydrogen/Placebo Minocycline)	積觸鬱築鬱淵壓鬱淵鬱 = 簾壓顧製鏇襯憲淵構蓋簾遞艱範衊鏇糧遞淵襯 (鬱壓夢齋鏇齋膚顧積顧, 繭壓網鏇齋夢窪膚製鏇 ~ 築選製願鑰簾壓製壓蓋) 更多
ASCO 12023 \| ASCO 22023 人工标引	N/A	鳞状非小细胞肺癌一线	45	Tislelizumab+Carboplatin+pm-Pac	鏇糧獵糧壓壓鹹鹹餘鏇(顧觸齋遞艱繭構繭餘窪) = The most common TRAE were alopecia (91.1%), leukopenia (80%), peripheral neurosensory numbness (55.6%) and extremity pain (24.4%). The most common grade 3 or higher AE was neutropenia (33.3%), which is commonly associated with chemotherapy. 糧膚淵選鑰觸襯餘鏇壓 (衊艱構襯鏇鏇繭膚繭鬱 )	积极	2023-05-31
				Tislelizumab+Carboplatin+pm-Pac (PD-L1 expression＜1%)